• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

News

Liquidia announces that the FDA will miss the PDUFA goal date for review of Yutrepia sNDA to add PH-ILD indication

According to Liquidia Corporation, the FDA has informed the company that the agency will not meet the PDUFA goal date of January 24, 2004 for completion of the review of Liquidia's sNDA to add an indication for pulmonary hypertension associated with interstitial lung disease (PH-ILD) for Yutrepia treprostinil DPI. The company said that the FDA "informed the Company … [Read more...] about Liquidia announces that the FDA will miss the PDUFA goal date for review of Yutrepia sNDA to add PH-ILD indication

Recipharm and Medspray extend their partnership on Resyca SMIs to include nasal delivery

CDMO Recipharm has announced an extension of its existing partnership with spray nozzle developer and manufacturer Medspray to include development of soft mist nasal delivery devices. In February 2021, Recipharm and Medspray announced the launch of their joint venture Resyca to develop soft mist inhalation products using Medspray nozzle technology. The new … [Read more...] about Recipharm and Medspray extend their partnership on Resyca SMIs to include nasal delivery

AstraZeneca launches Airsupra albuterol / budesonide MDI in the US

AstraZeneca has announced the US launch of its Airsupra albuterol / budesonide MDI, which was approved by the FDA in January 2023 for the treatment of asthma in people aged 18 and over. Airsupra (PT027) was developed by AstraZeneca subsidiary Pearl Therapeutics. The company points out that the MDI is the only approved SABA/ICS inhaler and the only one that includes … [Read more...] about AstraZeneca launches Airsupra albuterol / budesonide MDI in the US

Inhalation Sciences and Actarmo Medical team up to offer OINDP development services

Swedish aerosol research specialists Inhalation Sciences AB (ISAB) have announced a new partnership with German OINDP development company Actarmo Medical to offer development services for inhalation products from preclinical through formulation and device development and clinical trial supplies. ISAB says that the partnership is part of a new emphasis on its … [Read more...] about Inhalation Sciences and Actarmo Medical team up to offer OINDP development services

FDA issues CRL to Satsuma’s NDA for STS101 intranasal dry powder DHE for the treatment of migraine

According to Satsuma Pharmaceuticals parent company Shin Nippon Biomedical Laboratories, the FDA has issued a complete response letter to Satsuma's NDA for STS101 dihydroergotamine nasal powder for the treatment of migraine. SNBL said that the CRL cited CMC issues only and did not request any additional clinical data or new clinical trials. The company added that it … [Read more...] about FDA issues CRL to Satsuma’s NDA for STS101 intranasal dry powder DHE for the treatment of migraine

Kindeva Drug Delivery acquires Summit Biosciences

Kindeva Drug Delivery has acquired CDMO Summit Biosciences, a nasal drug delivery specialist, the company announced. In 2020, Summit said that it had concluded a significant expansion to its facility in Lexington, KY, USA, bringing the facility to 44,000 sq ft. According to the Kindeva press release, the Summit cGMP facility in Kentucky is currently 55,000 sq ft and … [Read more...] about Kindeva Drug Delivery acquires Summit Biosciences

PureIMS says it is on a path to an abbreviated application for Levodopa Cyclops DPI based on Phase 1 trial results

PureIMS announced that a Phase 1 PK study that compared the company's Levodopa Cyclops to Inbrija levodopa DPI, demonstrated "high comparability with a marketed inhaled levodopa product," with faster initial absorption and no safety or tolerability concerns reported. The company announced the initiation of the Phase 1 study in August 2023. The company says that it … [Read more...] about PureIMS says it is on a path to an abbreviated application for Levodopa Cyclops DPI based on Phase 1 trial results

Cyrano raises $9 million for continued development of CYR-064 intranasal theophylline for the treatment of hyposmia

Cyrano Therapeutics said that the company will use proceeds from a $9 million Series B financing round to fund an ongoing Phase 2 trial of CYR-064 theophylline nasal spray for the treatment of loss of smell due to viral infection. Cyrano previously announced in December 2020 that it had raised $12.8 million in Series A financing for a Phase 2 trial of CYR-064. In … [Read more...] about Cyrano raises $9 million for continued development of CYR-064 intranasal theophylline for the treatment of hyposmia

Intertek joins IPAC-RS as an associate member

Contract research company Intertek announced that it has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) as an associate member, citing its long-term commitment to support for OINDP development. In the announcement Intertek pointed to its Centre of Excellence for the development of inhaled and nasal drugs, which … [Read more...] about Intertek joins IPAC-RS as an associate member

Gary Pitcairn joins Iconovo as Senior Scientific Advisor

Iconovo has announced that OINDP expert Gary Pitcairn will join the company as Senior Scientific Advisor to support development projects, particularly reformulation of drugs for inhalation. Pitcairn, who was most recently Chief Scientific Officer at Nanologica, previously headed respiratory groups at AstraZeneca, Mylan, Pfizer, and Pharmaceutical Profiles. He is also … [Read more...] about Gary Pitcairn joins Iconovo as Senior Scientific Advisor

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Interim pages omitted …
  • Page 417
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews